Tag: Biotech and Pharma

 Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

Johnson & Johnson stock was slipping Wednesday after the pharmaceutical company beat expectations for its second-quarter earnings.

Novo Nordisk and Eli Lilly shares slid Wednesday after Roche announced promising early-stage trial data from its latest obesity drug candidate.

Pfizer on Thursday said it will move forward with a once-daily version of its weight loss pill, danuglipron, after it saw “encouraging” data in an ongoing early-stage study.

The Grifols family and Canadian fund Brookfield have agreed to launch a joint takeover bid for Spanish drugmaker Grifols  with the intent to delist it, the companies said in regulatory filings on Monday.

Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline.

 UK’s competition regulator said on Monday it has cleared U.S. medical equipment maker Thermo Fisher Scientific’s $3.1 billion deal to buy Swedish biotech firm Olink Holding AB.

Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after it failed to meet the trial’s primary efficacy goals.

Blockbuster weight loss drugs such as Wegovy and Ozempic may be associated with a rare eye condition, according to a new study released Wednesday. A Novo Nordisk spokesperson said there were “key methodological limitations” to the study

GSK’s London-listed shares fell even more swiftly than their ADRs to news that advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinated against respiratory syncytial virus.

Novo Nordisk’s hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world’s second-largest economy and the country estimated to hold the highest number of overweight or obese people.

Eurofins Scientific shares plunged on Monday after Muddy Waters Research said in a report it had started shorting the laboratory-services company, alleging founder and Chief Executive Gilles Martin has spent decades “covertly enriching” himself through improper real-estate deals.

Shares of Denmark’s Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results.

Sarepta Therapeutics Inc.’s (SRPT) gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.

Johnson & Johnson has agreed to pay $700 million to settle an investigation by 42 U.S. states and Washington, D.C. into its marketing of baby powder and other talc-based products blamed for allegedly causing cancer.

A panel of independent advisors to the Food and Drug Administration on Monday recommended Eli Lilly’s Alzheimer’s drug donanemab, paving the way for the treatment to receive full approval in the U.S. later this year.

Shares of GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer, to go forward, in a blow for the British drugmaker.

Merck & Co. Inc. announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.

Αύξηση κατά 15,9% παρουσιάζουν τα συνολικά κέρδη προ φόρων, τόκων και αποσβέσεων (EBITDA) του Ομίλου της Lavipharm για το Α’ τρίμηνο του 2024, τα οποία διαμορφώθηκαν σε €2,85 εκατ. έναντι €2,46 εκατ. κατά το αντίστοιχο διάστημα του προηγούμενου έτους, σύμφωνα με σχετική ανακοίνωση.

Pharmaceutical company AstraZeneca on Tuesday said it planned to increase its total revenue to $80 billion by 2030 — up 75% from $45.8 billion in 2023.